Retina Associates, located in Tucson, Arizona, delivers the highest quality ophthalmological/retinal care. Led by Cameron Javid, MD, Retina Associates also participates in national/international clinical trials to improve care and offer the latest treatment options for patients.
A February 2023 article in the pharmaceutical magazine, BioSpace, reported that the FDA approved Syfovre to treat geographic atrophy (GA), a condition that can lead to blindness. GA causes the retinal cells in some areas to waste away in some patients with age-related macular degeneration.
Five million people globally have this condition, and up until now, patients could not do anything but watch their vision deteriorate because of the condition. The lesions that interfere with vision impact central vision within 2.5 years.
Researcher Eleonora Lad stated the findings from the Phase III OAKS and DERBY trials, which supported the approval of the drug, might be the most important event in retinal ophthalmology in a decade. The DERBY trial showed that the drug reduced lesions up to 36 percent between 18-24 months.
Syfovre, an injection, was approved in February 2023. This is the first FDA-approved medication to treat advanced dry macular degeneration.
